TEG improves anticoagulation management during cardiopulmonary bypass complicated by antiphospholipid syndrome. Issue 6 (17th April 2020)

• Record Type: Journal Article
• Authors: Nakajima, Tomomi; Kato, Hideyuki; Mathis, Bryan J.; Hiramatsu, Yuji; Sakamoto, Hiroaki
• Is Part Of: Journal of cardiac surgery. Volume 35:Issue 6(2020)
• Page Start: 1354
• Page End: 1356
• Publication Date: 2020-04-17
• Subjects: antiphospholipid syndrome -- TEG and cardiac surgery; Heart -- Surgery -- Periodicals; 617.412005
• DOI: 10.1111/jocs.14557
• Languages: English
• ISSNs: 0886-0440

Abstract

Abstract: Background and Aim: Cardiopulmonary bypass (CPB) in antiphospholipid syndrome (APS) patients carries a high risk of thrombosis and hemorrhage. However, optimal anticoagulation surveillance methods have not been established and heparin optimization has not yet been totally validated as reflective of anticoagulation status. Methods and Result: Here, a 45‐year‐old female with APS underwent mitral valvuloplasty due to infective endocarditis. We used a perioperative, in vitro, heparin‐activated clotting time (ACT) titration line coupled with synergistic, intraoperative thromboelastography (TEG) to monitor coagulation activity. After the ACT target was reached, TEG monitored the suppression of both intrinsic and extrinsic coagulation activity throughout the surgery. Conclusion: TEG thus provided valuable temporal information on both intrinsic and extrinsic coagulation suppression validating heparin‐ACT titration targets.